Browse EyeWorld Weekly ophthalmology news on EyeWorld.org. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ Study: Standalone trabeculotomy/viscodilation 24-month outcomes ➤ Proof of concept for dropless immunosuppression after PK ➤ Topline Phase 2 data for high-dose aflibercept in wet AMD ➤ Companies enter licensing agreement for investigational ophthalmic therapies ➤ ASCRS news and events
➤ Phase 3 clinical trials compare brolucizumab to aflibercept for DME ➤ Study: Randomized clinical trial evaluates combination drops, drop monotherapy, and dropless cataract surgery ➤ Commercial rights agreement for triamcinolone drug candidate ➤ ASCRS news and events
➤ Orphan drug designation granted for retinitis pigmentosa treatment ➤ Licensing agreement for progressive myopia treatment ➤ Study: Gene editing prevents Fuchs in mice ➤ Enrollment complete for Phase 3 program evaluating anti-inflammatory, immunomodulation drug for DED ➤ ASCRS news and events
➤ Study: Music reduces anxiety, hypertensive events in cataract surgery ➤ Phase 2 study results for investigational dry AMD treatment ➤ Phase 3 topline results for wet AMD therapeutic ➤ FDA accepts BLA for faricimab ➤ ASCRS news and events
➤ Full results from Phase 3 study for presbyopia-correcting eye drop ➤ Cells from two donors treat dozens of patients with corneal endothelial disease ➤ Study: Dry eye treatment reduces halos after cataract surgery ➤ NDA accepted for IND application for novel, investigational dry eye drug ➤ Acquisition of ophthalmic drug candidate ➤ ASCRS events
➤ FDA grants IDE for MIGS device to start pivotal trial ➤ Breakthrough therapy designation granted for possible Stargardt treatment ➤ Refractive surgery uptick continues ➤ First patient dosed in trial for light-activated optogenetic monotherapy for RP ➤ Diagnostic device company acquires ophthalmic device manufacturer ➤ Two ophthalmic companies partner ➤ ASCRS news and events
➤ New visual prosthesis heads to clinical trial ➤ FDA grants Fast Track designation to investigational wet AMD therapy ➤ Patient enrollment complete in Phase 3 trial for investigational, first-in-class eye drop for DED ➤ FDA agrees to pivotal trial design for investigational treatment of geographic atrophy secondary to AMD ➤ ASCRS news and events
➤ Combination pharmaceutical therapy being investigated for presbyopia meets study endpoints ➤ Positive results in Phase 2 clinical trial for IOP-lowering agent ➤ Phase 3 results from study of gene therapy for retinal neurodegenerative diseases ➤ Positive safety results in Phase 1 anti-VEGF treatment ➤ ASCRS news and events
➤ FDA approves drops for vernal keratoconjunctivitis ➤ Data from investigational first-in-class dry eye therapy ➤ FDA accepts BLA for Port Delivery System of ranibizumab ➤ Companies enter collaboration to investigate treatments for dry AMD ➤ ASCRS news and events
➤ Survey: 96% of ophthalmologists vaccinated against COVID-19 ➤ Phase 2b/3 results from trial for Demodex blepharitis ➤ Data from ongoing Phase 2a study of therapy for geographic atrophy ➤ First patient enrolled in Phase 2 study of nasal spray for neurotrophic keratopathy ➤ Next ASCRS Journal Club on July 8
Get the latest ophthalmology news delivered to your inbox every Friday.